Frederick O. Cope, PhD, will be joining Neoprobe as its vice president (VP) of pharmaceutical research and clinical development.
Cope has most recently served as the assistant director for research and head of program research development for the Ohio State University Comprehensive Cancer Center, the James Cancer Hospital and the Richard J. Solove Research Institute. He also served for a number of years as the Ernest W. Volwiler Fellow and head of the Cancer and AIDS Research Effort for Abbot Laboratories-Ross Division.
Cope is joining the company at an "exciting point in its corporate development as we work through the pivotal clinical trials and prepare for the regulatory submissions to support marketing clearance for Lymphoseek and as we make visible progress in reinvigorating our development activities related to RIGScan CR," according to David Bupp, Neoprobe's president and CEO.